English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Cholera is caused by Vibrio cholerae strains belonging to two serogroups, O1 and O139, based on their LPS structure. Serogroup O1, which is responsible for the seventh cholera pandemic, is divided into three serotypes, Inaba, Ogawa and Hikojima (1). In the year 2002, World Health Organization (WHO) estimated that over 220,000 people were stricken with cholera each year. Natural infection and currently available vaccines offer incomplete protection of relatively short duration. The long-term control of cholera depends on good personal hygiene, uncontaminated water supply and appropriate sewage disposal. However, the improvement of hygiene is a distant goal for many countries. Thus, the availability of an effective cholera vaccine is important for the prevention of cholera in these countries. The only vaccines recommended from WHO for massive immunization of population in cholera epidemic regions is WC/rBS per oral cell vaccines. The vaccines CVD 103-HgR is used mainly for immunization of people who travel in cholera epidemic regions. A conjugate vaccine composed of the detoxified LPS of V. cholerae O1 serotype Inaba bound to cholera toxin elicits vibriocidal antibodies against both Ogawa and Inaba serotypes (2,3). The Ogawa and Inaba serotypes of V. cholerae O1 differ only by a 2-O-methyl group that is present in the non-reducing terminal sugar of the Ogawa O-specific polysaccharide (O-SP) of the LPS, but is absent from the Inaba O-SP (4,5,6). It is thus most likely that the protection induced in vaccine trials by Ogawa whole-cell vaccines is due to the induction of antibodies recognizing only this serotype-specific antigenic determinant. Abstract

makedonsko farmacevtski bilten/makedonski farmacevtski bilten

Design, synthesis and determination of physical and chemical characteristics of glycoconjugates as model for oligosaccharide vaccines against vibrio cholerae